US Department of Defense awards $2.2 M CDN research contract toTwinstrand Therapeutics Inc.
Development of medical countermeasure to ricin
Twinstrand Therapeutics announced that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning. The two-year $2.2 M CDN ($1.9 M USD) contract was granted, in a competitive process, by the United States Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense.
Dr. Thor Borgford, Twinstrand President & CEO, commented "This award is an important recognition of Twinstrand's growing clinical and drug development capabilities. Importantly, we expect the program will lead the company to a significant product opportunity. It is worth noting further that Twinstrand is able to leverage pre-existing therapeutic assets in the development of the countermeasure that make the program an ideal complement to our oncology drug platform."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.